Generali Investments CEE investicni spolecnost a.s. Grows Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Generali Investments CEE significantly increased its stake in Sarepta Therapeutics by over 5,166% in the 2nd quarter, owning approximately 105,326 shares valued at $1.8 million.
• Analysts have recently adjusted their ratings for Sarepta, with a mix of Buy and Sell ratings leading to a consensus price target of $39.32 and some analysts predicting a steep decline in share value.
• Sarepta Therapeutics reported earnings of $2.02 EPS, exceeding estimates and showcasing a revenue increase of 68.4% year-over-year, despite a challenging forecast for the company moving forward.

Generali Investments CEE investicni spolecnost a.s. lifted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 5,166.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 105,326 shares of the biotechnology company's stock after buying an additional 103,326 shares during the quarter. Generali Investments CEE investicni spolecnost a.s. owned approximately 0.11% of Sarepta Therapeutics worth $1,801,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of SRPT. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics in the first quarter worth $30,000. Center for Financial Planning Inc. bought a new stake in Sarepta Therapeutics in the first quarter worth $31,000. Ancora Advisors LLC increased its position in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 300 shares during the last quarter. Banque Transatlantique SA bought a new stake in Sarepta Therapeutics in the first quarter worth $44,000. Finally, Pandora Wealth Inc. bought a new stake in Sarepta Therapeutics in the first quarter worth $45,000. Institutional investors own 86.68% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on SRPT shares. Jefferies Financial Group reduced their price target on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Thursday, July 24th. Baird R W cut shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 18th. Citigroup assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 22nd. They set a "sell" rating on the stock. Mizuho reiterated a "neutral" rating and set a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Finally, Sanford C. Bernstein assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. They set a "market perform" rating and a $13.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and a consensus price target of $39.32.

Sarepta Therapeutics Price Performance

SRPT stock opened at $19.27 on Wednesday. The stock has a 50-day moving average price of $17.86 and a two-hundred day moving average price of $33.83. The stock has a market cap of $1.88 billion, a PE ratio of -22.15 and a beta of 0.49. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million during the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company's revenue was up 68.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.07 EPS. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.